Risk of Pancreatic Adenocarcinoma: Disparity Between African Americans and Other Race/ethnic Groups
Overview
Affiliations
Background: African Americans have a higher incidence of pancreatic adenocarcinoma compared with non-Hispanic whites. Whether other clinical differences exist between these two groups is not well known.
Methods: The authors conducted a population-based retrospective analysis of all patients with pancreatic adenocarcinoma in both a regional and a statewide database between 1988 and 1998. Their goal was to evaluate differences in incidence rates, clinical presentation, including age at diagnosis, gender, and tumor characteristics, and treatment among race/ethnic groups.
Results: African Americans had a higher age-adjusted incidence rate of pancreatic adenocarcinoma (8.78) compared with non-Hispanic whites (5.89), Hispanics (5.09), Asians (4.75), and all race/ethnicities combined (5.82). African Americans also presented at a later stage of disease and received less surgery than all other race/ethnicities, despite equal availability of medical insurance. The analyses also revealed gender differences. In general, males maintained a higher incidence rate of pancreatic adenocarcinoma than females across all race/ethnicities. In all race/ethnic groups, females were diagnosed at an older age and an earlier stage of disease than males. The proportional hazard mortality ratio for females age < 60 was significantly less than that for males in the same age group (P < 0.02), even after accounting for stage and treatment.
Conclusions: African Americans in California had a higher incidence rate of pancreatic adenocarcinoma, had a slightly higher risk of presenting with advanced-stage disease and with nonresectable tumors (i.e., tumors located in the body or tail of the pancreas), and underwent less surgical treatment than all other race/ethnicities. Younger females in all race/ethnic groups had a survival advantage over males of the same age.
AKR1B10 and digestive tumors development: a review.
Shen Y, Qiu A, Huang X, Wen X, Shehzadi S, He Y Front Immunol. 2024; 15:1462174.
PMID: 39737179 PMC: 11682995. DOI: 10.3389/fimmu.2024.1462174.
Permuth J, Park M, Chen D, Basinski T, Powers B, Gwede C Front Oncol. 2024; 14:1362244.
PMID: 39109281 PMC: 11300308. DOI: 10.3389/fonc.2024.1362244.
Survival and prognostic factors among hospitalized pancreatic cancer patients in northwestern Iran.
Vahedi L, Asvadi Kermani T, Asghari-Jafarabadi M, Asghari E, Mohammadi S, Khameneh A J Res Med Sci. 2023; 28:4.
PMID: 36974115 PMC: 10039100. DOI: 10.4103/jrms.jrms_54_21.
From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care.
Herremans K, Riner A, Charles A, Balch J, Vudatha V, Freudenberger D Front Oncol. 2022; 12:1086779.
PMID: 36568255 PMC: 9779942. DOI: 10.3389/fonc.2022.1086779.
Thomas A, Sharma R, Kwon W, Sugahara K, Chabot J, Schrope B J Gastrointest Surg. 2022; 26(8):1647-1662.
PMID: 35501551 DOI: 10.1007/s11605-022-05320-1.